Filter
520
Filtered Results: 520
Text search:
in
vitro
diagnostic
tests
Featured
Recommendations
74
New Publications
105
Language
Document type
No document type
233
Guidelines
137
Studies & Reports
66
Manuals
47
Fact sheets
16
Strategic & Response Plan
13
Training Material
5
Resource Platforms
2
Situation Updates
1
Countries / Regions
India
25
Germany
15
Global
12
Latin America and the Carribbean
12
South Africa
11
Western and Central Europe
10
Africa
9
Kenya
7
Russia
7
Tanzania
6
Rwanda
5
Brazil
5
Ethiopia
5
Sierra Leone
4
Cameroon
4
Nigeria
4
Eastern Europe
4
Namibia
4
Nepal
3
Senegal
3
Congo-Brazzaville
3
Burkina Faso
3
Malawi
3
West and Central Africa
3
Uganda
3
Zambia
3
Ukraine
2
Benin
2
Togo
2
Niger
2
Haiti
2
Asia
2
Venezuela
2
Congo, Democratic Republic of
2
Middle East and North Africa
2
France
2
East and Southern Africa
2
Côte d’Ivoire / Ivory Coast
2
Argentina
2
Bangladesh
2
Mali
2
Myanmar / Burma
2
Madagascar
2
Eswatini/ Swaziland
2
Colombia
1
Turkey
1
Gambia
1
Chile
1
Syria
1
Albania
1
Canada
1
Laos
1
Burundi
1
Peru
1
Zimbabwe
1
Philippines
1
Guinea
1
USA
1
South–East Asia Region
1
Luxembourg
1
North America
1
Belgium
1
Bolivia
1
Djibouti
1
Yemen
1
Angola
1
South Sudan
1
Indonesia
1
Liberia
1
Authors & Publishers
Publication Years
Category
Countries
119
Clinical Guidelines
110
Pharmacy & Technologies
38
Public Health
16
Women & Child Health
16
Key Resources
10
Toolboxes
TB
72
COVID-19
69
HIV
65
NTDs
42
AMR
32
Rapid Response
22
Pharmacy
16
Refugee
12
Ebola & Marburg
12
Zika
12
Mental Health
9
Caregiver
8
Polio
6
Planetary Health
4
Global Health Education
3
Cholera
2
Specific Hazards
1
Natural Hazards
1
Health Financing Toolbox
1
NCDs
1
Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to
prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go...
There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.
Supply of essential medicines and health technologies (6 April 2020)
This paper is one of a set of technical guidance papers developed by the WHO Regional Office for Europe to provide practical information and resources for decision-makers on measures to strengthen the health system response to C...
The guidelines reiterate that the general principles of ethics for biomedical research involving human participants shall also be applicable. In addition, the guidelines specify unique provisions for stem cells, because of their inherent property for unlimited proliferation, differentiation to cells...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...
About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im...
The WHO operational handbook on tuberculosis: tuberculosis preventive treatment is the companion, implementation guide to the 2020 WHO guidelines on TB preventive treatment.[1] Just as these guidelines are the first to be released under the rubric of the WHO consolidated TB guidelines, this handbook...
Antimicrobial resistance (AMR) has emerged as a major public health problem all over the world. Infections caused by resistant microbes fail to respond to treatment, resulting in prolonged illness and greater risk of death. This document focuses on the mechanism to develop a practically applicable h...
WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended
The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ...
Snakebite is an acute life threatening time limiting medical emergency. It is a preventable public
health hazard often faced by rural population in tropical and subtropical countries with heavy
rainfall and humid climate.
Modern healthcare has given rise to extremely complex and multifaceted ethical dilemmas. All too often physicians are unprepared to manage these competently. This publication is specifically structured to reinforce and strengthen the ethical mindset and prac...
Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio...
The current document is anupdate of the guidelines developed by the EUCAST subcommittee on detection of resistance mechanisms. The EUCAST Steering Committee has carried out the current update. The document has been developed mainly for routine use in clinical laboratories and doesnot cover technical...
Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,...
The objective of the 2022 Compendium is to compile and highlight emerging innovative health technologies for low-resource settings. It presents a snapshot of technologies that are solutions to an unmet medical/health technology need or are likely to improve health outcomes and the quality of life. H...
Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM...
This resource consists of technical guidelines for District Medical Officers, counselors and laboratory technicians for second-line antiretroviral therapy drugs, operational guidelines for pilot roll-out in two centres and laboratory guidelines for viral-load testing and standard operating procedure...
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ...
